Overview

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This study is designed to explore the efficacy and safety of anlotinib combined with benmelstobart and AG (nab-paclitaxel and gemcitabine) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in metastatic pancreatic cancer.

Phase:

PHASE2

Details

Lead Sponsor:

RenJi Hospital

Collaborator:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Treatments:

130-nm albumin-bound paclitaxel
anlotinib
Gemcitabine